Skip to main content
SpringerLink
Log in

Treatment of Pediatric Hypertension: Lessons Learned from Recent Clinical Trials

  • Pediatrics (S Gidding, Section Editor)
  • Published:
Current Cardiovascular Risk Reports Aims and scope Submit manuscript

Abstract

Historically, drugs prescribed for children have not been studied rigorously to assess their efficacy and safety, or appropriateness of dosing regimens. The passage of the Federal Drug Administration Modernization Act in 1997 heralded an era of increased rigor with respect to pediatric drug development by providing financial incentives to industry sponsors for conducting pharmaceutical trials in children. Subsequent legislative efforts have facilitated ongoing attention to this area. Antihypertensive drugs represent one of the largest groups of medications impacted by these efforts. Consequently, a growing number of antihypertensive medications from different classes have been studied in children and adolescents, resulting in more of these agents receiving FDA-approved labeling for use in children and adolescents.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. Flynn JT. Pediatric use of antihypertensive medications: much more to learn. Curr Ther Res. 2001;62(4):314–28.

    Article  CAS  Google Scholar 

  2. Shirkey H, editor. Conference of Professional and Scientific Societies, 27–28 June 1963; Chicago, IL.

  3. US Food and Drug Administration. Food and Drug Administration Modernization Act of 1997. http://www.fda.gov/RegulatoryInformation/Legislation/FederalFoodDrugandCosmeticActFDCAct/SignificantAmendmentstotheFDCAct/FDAMA/FullTextofFDAMAlaw/default.htm. Accessed 8 Jul 2014.

  4. Pediatric Research Equity Act of 2003. http://www.fda.gov/downloads/drugs/developmentapprovalprocess/developmentresources/ucm077853.pdf. Accessed 8 Jul 2014.

  5. Best Pharmaceuticals for Children Act. http://www.fda.gov/RegulatoryInformation/Legislation/FederalFoodDrugandCosmeticActFDCAct/SignificantAmendmentstotheFDCAct/ucm148011.htm. Accessed 8 Jul 2014.

  6. Public Law 0112-144, The Food and Drug Administration Safety amd Innovation Act. http://www.gpo.gov/fdsys/pkg/PLAW-112publ144/pdf/PLAW-112publ144.pdf. Accessed 8 Jul 2014.

  7. Pasquali SK, Sanders SP, Li JS. Oral antihypertensive trial design and analysis under the pediatric exclusivity provision. Am Heart J. 2002;144(4):608–14.

    Article  PubMed  Google Scholar 

  8. United States Food and Drug Administration. Written Requests Issued. http://www.fda.gov/drugs/developmentapprovalprocess/developmentresources/ucm050002.htm. Accessed 8 Jul 2014.

  9. United States Food and Drug Administration. Drugs to Which FDA has Granted Pediatric Exclusivity for Pediatric Studies under Section 505A of the Federal Food, Drug, and Cosmetic Act. http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/UCM223058.pdf. Accessed 8 Jul 2014.

  10. Benjamin Jr DK, Smith PB, Jadhav P, Gobburu JV, Murphy MD, Hasselblad V, et al. Pediatric antihypertensive trial failures: analysis of end points and dose range. Hypertension. 2008;51(4):834–40.

  11. Meyers RS, Siu A. Pharmacotherapy review of chronic pediatric hypertension. Clin Ther. 2011;33(10):1331–56. doi:10.1016/j.clinthera.2011.09.003.

    Article  CAS  PubMed  Google Scholar 

  12. DiBianco R. Angiotensin converting enzyme inhibition. Unique and effective therapy for hypertension and congestive heart failure. Postgrad Med. 1985;78(5):229–41. 244, 247–8.

    CAS  PubMed  Google Scholar 

  13. Smith CG, Vane JR. The discovery of captopril. FASEB J. 2003;17(8):788–9. doi:10.1096/fj.03-0093life.

    Article  CAS  PubMed  Google Scholar 

  14. Oberfield SE, Case DB, Levine LS, Rapaport R, Rauh W, New MI. Use of the oral angiotensin I-converting enzyme inhibitor (captopril) in childhood malignant hypertension. J Pediatr. 1979;95(4):641–4.

    Article  CAS  PubMed  Google Scholar 

  15. Mirkin BL, Newman TJ. Efficacy and safety of captopril in the treatment of severe childhood hypertension: report of the International Collaborative Study Group. Pediatrics. 1985;75(6):1091–100.

    CAS  PubMed  Google Scholar 

  16. Sinaiko AR, Kashtan CE, Mirkin BL. Antihypertensive drug therapy with captopril in children and adolescents. Clin Exp Hypertens A. 1986;8(4–5):829–39.

    Article  CAS  PubMed  Google Scholar 

  17. Sinaiko AR, Mirkin BL, Hendrick DA, Green TP, O'Dea RF. Antihypertensive effect and elimination kinetics of captopril in hypertensive children with renal disease. J Pediatr. 1983;103(5):799–805.

    Article  CAS  PubMed  Google Scholar 

  18. Tack ED, Perlman JM. Renal failure in sick hypertensive premature infants receiving captopril therapy. J Pediatr. 1988;112(5):805–10.

    Article  CAS  PubMed  Google Scholar 

  19. National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics. 2004;114(2 Suppl 4th Report):555–76.

    Article  Google Scholar 

  20. Wells T, Frame V, Soffer B, Shaw W, Zhang Z, Herrera P, et al. A double-blind, placebo-controlled, dose-response study of the effectiveness and safety of enalapril for children with hypertension. J Clin Pharmacol. 2002;42(8):870–80.

    Article  CAS  PubMed  Google Scholar 

  21. Soffer B, Zhang Z, Miller K, Vogt BA, Shahinfar S. A double-blind, placebo-controlled, dose-response study of the effectiveness and safety of lisinopril for children with hypertension. Am J Hypertens. 2003;16(10):795–800.

    Article  CAS  PubMed  Google Scholar 

  22. United States Food and Drug Administration. New pediatric labeling information database. http://www.accessdata.fda.gov/scripts/sda/sdNavigation.cfm?sd=labelingdatabase. Accessed 8 Jul 2014.

  23. Li JS, Berezny K, Kilaru R, Hazan L, Portman R, Hogg R, et al. Is the extrapolated adult dose of fosinopril safe and effective in treating hypertensive children? Hypertension. 2004;44(3):289–93. doi:10.1161/01.HYP.0000138069.68413.f0.

    Article  CAS  PubMed  Google Scholar 

  24. Menon S, Berezny KY, Kilaru R, Benjamin Jr DK, Kay JD, Hazan L, et al. Racial differences are seen in blood pressure response to fosinopril in hypertensive children. Am Heart J. 2006;152(2):394–9. doi:10.1016/j.ahj.2005.12.025.

    Article  CAS  PubMed  Google Scholar 

  25. Brewster LM, van Montfrans GA, Kleijnen J. Systematic review: antihypertensive drug therapy in black patients. Ann Intern Med. 2004;141(8):614–27.

    Article  PubMed  Google Scholar 

  26. United States Food and Drug Administration. Summaries of medical and clinical pharmacology reviews. http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/UCM161981.pdf. Accessed 8 Jul 2014.

  27. United States Food and Drug Adminsitration. Summaries of medical and clinical pharmacology reviews. http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/UCM163259.pdf. Accessed 8 Jul 2014.

  28. Shahinfar S, Cano F, Soffer BA, Ahmed T, Santoro EP, Zhang Z, et al. A double-blind, dose-response study of losartan in hypertensive children. Am J Hypertens. 2005;18(2 Pt 1):183–90. doi:10.1016/j.amjhyper.2004.09.009.

    Article  CAS  PubMed  Google Scholar 

  29. Webb NJ, Wells TG, Shahinfar S, Massaad R, Dankner WM, Lam C, et al. A randomized, open-label, dose-response study of losartan in hypertensive children. Clin J Am Soc Nephrol. 2014. doi:10.2215/CJN.11111113. Study showed that losartan is effective in lowering the blood pressure in children aged 6 months to 6 years, though no dose–response relationship was observed.

    PubMed  Google Scholar 

  30. Trachtman H, Hainer JW, Sugg J, Teng R, Sorof JM, Radcliffe J. Efficacy, safety, and pharmacokinetics of candesartan cilexetil in hypertensive children aged 6 to 17 years. J Clin Hypertens (Greenwich). 2008;10(10):743–50. doi:10.1111/j.1751-7176.2008.00022.x.

    Article  CAS  Google Scholar 

  31. Schaefer F, van de Walle J, Zurowska A, Gimpel C, van Hoeck K, Drozdz D, et al. Efficacy, safety and pharmacokinetics of candesartan cilexetil in hypertensive children from 1 to less than 6 years of age. J Hypertens. 2010;28(5):1083–90. doi:10.1097/HJH.0b013e328336b86b.

    Article  CAS  PubMed  Google Scholar 

  32. Tullus K. Safety concerns of angiotensin II receptor blockers in preschool children. Arch Dis Child. 2011;96(9):881–2. doi:10.1136/archdischild-2011-300172.

    Article  PubMed  Google Scholar 

  33. Hazan L, Hernandez Rodriguez OA, Bhorat AE, Miyazaki K, Tao B, Heyrman R. A double-blind, dose-response study of the efficacy and safety of olmesartan medoxomil in children and adolescents with hypertension. Hypertension. 2010;55(6):1323–30. doi:10.1161/HYPERTENSIONAHA.109.147702. One of the few pediatric trials to compare the efficacy of angiotensin blockade in black and predominantly non-black patient cohorts.

    Article  CAS  PubMed  Google Scholar 

  34. Sakarcan A, Tenney F, Wilson JT, Stewart JJ, Adcock KG, Wells TG, et al. The pharmacokinetics of irbesartan in hypertensive children and adolescents. J Clin Pharmacol. 2001;41(7):742–9.

    Article  CAS  PubMed  Google Scholar 

  35. Franscini LM, Von Vigier RO, Pfister R, Casaulta-Aebischer C, Fossali E, Bianchetti MG. Effectiveness and safety of the angiotensin II antagonist irbesartan in children with chronic kidney diseases. Am J Hypertens. 2002;15(12):1057–63.

    Article  CAS  PubMed  Google Scholar 

  36. United States Food and Drug Administration. Summaries of medical and clinical pharmacology reviews. http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/UCM162982.pdf. Accessed 8 Jul 2014.

  37. Trachtman H, Frank R, Mahan JD, Portman R, Restaino I, Matoo TK, et al. Clinical trial of extended-release felodipine in pediatric essential hypertension. Pediatr Nephrol. 2003;18(6):548–53. doi:10.1007/s00467-003-1134-0.

    PubMed  Google Scholar 

  38. Tallian KB, Nahata MC, Turman MA, Mahan JD, Hayes JR, Mentser MI. Efficacy of amlodipine in pediatric patients with hypertension. Pediatr Nephrol. 1999;13(4):304–10.

    Article  CAS  PubMed  Google Scholar 

  39. Flynn JT, Smoyer WE, Bunchman TE. Treatment of hypertensive children with amlodipine. Am J Hypertens. 2000;13(10):1061–6.

    Article  CAS  PubMed  Google Scholar 

  40. Rogan JW, Lyszkiewicz DA, Blowey D, Khattak S, Arbus GS, Koren G. A randomized prospective crossover trial of amlodipine in pediatric hypertension. Pediatr Nephrol. 2000;14(12):1083–7.

    Article  CAS  PubMed  Google Scholar 

  41. von Vigier RO, Franscini LM, Bianda ND, Pfister R, Casaulta Aebischer C, Bianchetti MG. Antihypertensive efficacy of amlodipine in children with chronic kidney diseases. J Hum Hypertens. 2001;15(6):387–91. doi:10.1038/sj.jhh.1001203.

    Article  Google Scholar 

  42. Andersen J, Groshong T, Tobias JD. Preliminary experience with amlodipine in the pediatric population. Am J Ther. 2006;13(3):198–204. doi:10.1097/01.mjt.0000147593.73888.d5.

    Article  PubMed  Google Scholar 

  43. Flynn JT. Efficacy and safety of prolonged amlodipine treatment in hypertensive children. Pediatr Nephrol. 2005;20(5):631–5. doi:10.1007/s00467-004-1781-9.

    Article  PubMed  Google Scholar 

  44. Flynn JT, Nahata MC, Mahan Jr JD, Portman RJ. Population pharmacokinetics of amlodipine in hypertensive children and adolescents. J Clin Pharmacol. 2006;46(8):905–16. doi:10.1177/0091270006289844.

    Article  CAS  PubMed  Google Scholar 

  45. Flynn JT, Newburger JW, Daniels SR, Sanders SP, Portman RJ, Hogg RJ, et al. A randomized, placebo-controlled trial of amlodipine in children with hypertension. J Pediatr. 2004;145(3):353–9. doi:10.1016/j.jpeds.2004.04.009.

    Article  CAS  PubMed  Google Scholar 

  46. Lyszkiewicz DA, Levichek Z, Kozer E, Yagev Y, Moretti M, Hard M, et al. Bioavailability of a pediatric amlodipine suspension. Pediatr Nephrol. 2003;18(7):675–8. doi:10.1007/s00467-003-1088-2.

    PubMed  Google Scholar 

  47. Nahata MC, Morosco RS, Hipple TF. Stability of amlodipine besylate in two liquid dosage forms. J Am Pharm Assoc (Wash). 1999;39(3):375–7.

    CAS  Google Scholar 

  48. Batisky DL, Sorof JM, Sugg J, Llewellyn M, Klibaner M, Hainer JW, et al. Efficacy and safety of extended release metoprolol succinate in hypertensive children 6 to 16 years of age: a clinical trial experience. J Pediatr. 2007;150(2):134–9, 139.e1. doi:10.1016/j.jpeds.2006.09.034.

  49. Sorof JM, Cargo P, Graepel J, Humphrey D, King E, Rolf C, et al. Beta-blocker/thiazide combination for treatment of hypertensive children: a randomized double-blind, placebo-controlled trial. Pediatr Nephrol. 2002;17(5):345–50. doi:10.1007/s00467-002-0851-0.

    Article  PubMed  Google Scholar 

  50. Schiffrin EL. Effects of aldosterone on the vasculature. Hypertension. 2006;47(3):312–8. doi:10.1161/01.HYP.0000201443.63240.a7.

    Article  CAS  PubMed  Google Scholar 

  51. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341(10):709–17. doi:10.1056/NEJM199909023411001.

    Article  CAS  PubMed  Google Scholar 

  52. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348(14):1309–21. doi:10.1056/NEJMoa030207.

    Article  CAS  PubMed  Google Scholar 

  53. Loggie JM. Hypertension in children and adolescents. II. Drug therapy. J Pediatr. 1969;74(4):640–54.

    Article  CAS  PubMed  Google Scholar 

  54. Li JS, Flynn JT, Portman R, Davis I, Ogawa M, Shi H, et al. The efficacy and safety of the novel aldosterone antagonist eplerenone in children with hypertension: a randomized, double-blind, dose-response study. J Pediatr. 2010;157(2):282–7. doi:10.1016/j.jpeds.2010.02.042.

    Article  CAS  PubMed  Google Scholar 

  55. Sullivan JE, Keefe D, Zhou Y, Satlin L, Fang H, Yan JH. Pharmacokinetics, safety profile, and efficacy of aliskiren in pediatric patients with hypertension. Clin Pediatr (Phila). 2013;52(7):599–607. doi:10.1177/0009922813483875.

    Article  Google Scholar 

  56. Welch WP, Yang W, Taylor-Zapata P, Flynn JT. Antihypertensive drug use by children: are the drugs labeled and indicated? J Clin Hypertens (Greenwich). 2012;14(6):388–95. doi:10.1111/j.1751-7176.2012.00656.x. Investigated the drugs prescribed to hypertensive children to determine to what extent antihypertensive medications used in children have FDA-approved pediatric labeling.

    Article  Google Scholar 

  57. Chaturvedi S, Lipszyc DH, Licht C, Craig JC, Parekh R. Pharmacological interventions for hypertension in children. Cochrane Database Syst Rev. 2014;2, CD008117. doi:10.1002/14651858.CD008117.pub2.

    PubMed  Google Scholar 

Download references

Compliance with Ethics Guidelines

Conflict of Interest

Joseph Flynn worked as a consultant for Pfizer, Inc. Flynn received royalties from Up-To-Date and Springer. Michael Ferguson worked as a consultant for Novartis, Inc. and received a grant from Genentech, Inc.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by the author.

Author information

Authors and Affiliations

  1. Division of Nephrology, Boston Children’s Hospital, Boston, MA, USA

    Michael A. Ferguson

  2. Division of Nephrology, Seattle Children’s Hospital, 4800 Sand Point Way NE, Seattle, WA, 98105, USA

    Joseph T. Flynn

Authors
  1. Michael A. Ferguson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Joseph T. Flynn
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Joseph T. Flynn.

Additional information

This article is part of the Topical Collection on Pediatrics

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ferguson, M.A., Flynn, J.T. Treatment of Pediatric Hypertension: Lessons Learned from Recent Clinical Trials. Curr Cardiovasc Risk Rep 8, 399 (2014). https://doi.org/10.1007/s12170-014-0399-0

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s12170-014-0399-0

Keywords

Search

Navigation